Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026 Key Takeaways: A…
WuXi AppTec wages buyback campaign as U.S. pressure mounts
The drug services provider has been battling to shore up its share price and suffered a sharp sell-off after being added to a U.S. list of firms with suspected military…
Tiny income, big dreams: can True Health become the next robotics champion?
The developer of medical devices is aiming to open up a commanding lead in the niche market for puncture and ablation robots, with the help of IPO proceeds Key Takeaways:…
Innovent’s $10.5 billion deal marks new model for China drugmakers
The Chinese biotech has added a major Pfizer collaboration to its growing roster of global deals, this time with a tighter commercial and profit-sharing partnership Key Takeaways: Co-commercialization deals…
Investors pile onto TenNor IPO with hopes for new type of gastric drug
The biotech enjoyed a standout Hong Kong share debut after hailing its novel anti-bacterial drug, now undergoing late-stage clinical tests, as a potential gamechanger Key Takeaways: The TenNor Therapeutics IPO…
Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
The global leap: Chinese biopharma, athletic brands dip toes in global waters
"To out-license drugs is a very handy and clever way for a win-win… but in terms of acquiring the businesses, that's going to be really tough." – Bradley Burgess Key…
Recent Articles
RELATED ARTICLES
-
Zeekr drives off Wall Street, heralding chilly year ahead for U.S. Chinese listings
- U.S. tries ‘monkey scaring’ to rid Wall Street of suspicious Chinese listings
- What listings? Small Chinese firms withdraw their Wall Street IPO applications
-
Faded AI beauty: After superstar debut Nuobikan falls back to earth
2635.HK
- Chinese medicine firm seeks elusive elixir of IPO success
-
Tongcheng’s rosy report fails to discuss the worrisome elephant in its house
0780.HK
